Rachelle Doody

[3] At Baylor College of Medicine Doody founded and directed the Alzheimer’s Disease and Memory Disorders Center, was the Effie Marie Cain Chair in Alzheimer’s Disease Research and, as of 2022, she is Distinguished Professor Emeritus.

[4] In 2016 she moved to Genentech / Roche where she is the Vice President, Global Head of Neurodegeneration and the Alzheimer's disease and Neurodegeneration Franchise Head in Product Development, Neuroscience at Roche Pharmaceutical Company and its US entity, Genentech.

Doody is primarily known for her work on the diagnosis and treatment of Alzheimer’s disease and related neurodegenerative disorders.

[6] Doody led the phase 2 and 3 development of donepezil, a medication for dementia, and has worked to broaden the diagnosis and treatment of Alzheimer's disease.

[2] In 2018 she received a Lifetime Achievement Award from the Clinical Trials in Alzheimer’s Disease Society.